HER2 can be detected in up to 47% of HNSCC patients and is associated with a worse prognosis [27], thus making it an attractive targeted for CAR-T cell therapy—HER2 targeting CAR-T cells have demonstrated good activity in early studies, with a decrease in tumor size of up to 56% in chickens engrafted with HER2-positive HNSCC cell lines [28]. This evidence concerns the gene ERBB2 and neoplasm.